Shares trading at 13 times its 2024 EPS estimate as a forward price-to-earnings (P/E) ratio may be a bargain if Merck begins ...
Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
Further evidence from Pfizer that it is no longer dependent on income from COVID-19 products could be a catalyst for the stock to sustain a rally. I believe both Merck and Pfizer deserve a buy ...
Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing ...
Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical ...
The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback